Treatment of anemia in chronic kidney disease: known, unknown, and both

References

• FisherJWErythropoietin: physiologic and pharmacologic aspectsProc Soc Exp Biol Med19972163583699402140
   PubMed Web of Science ®Google Scholar
• AdamsonJWErythropoietin: in vitro and in vivo studies of the regulation of erythropoiesisSchweiz Med Wochenschr1988118150115062849202
   PubMedGoogle Scholar
• JelkmannWErythropoietin: structure, control of production, and functionPhysiol Rev1992724494891557429
   PubMed Web of Science ®Google Scholar
• SalmonsonTDanielsonBGWikströmBThe pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjectsBr J Clin Pharmacol1990297097132378790
   PubMed Web of Science ®Google Scholar
• JelkmannWControl of erythropoietin gene expression and its use in medicineMethods Enzymol200743517919717998055
   PubMed Web of Science ®Google Scholar
• WangGLSemenzaGLGeneral involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxiaProc Natl Acad Sci U S A199390430443088387214
   PubMed Web of Science ®Google Scholar
• SemenzaGLHIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleusCell20011071311595178
   PubMed Web of Science ®Google Scholar
• ZhuHBunnHFSignal transduction. How do cells sense oxygen?Science200129244945111292863
   PubMed Web of Science ®Google Scholar
• BrueggeKJelkmannWMetzenEHydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylasesCurr Med Chem2007141853186217627521
   PubMed Web of Science ®Google Scholar
• SasakiHBothnerBDellAFukudaMCarbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNAJ Biol Chem198726212059120763624248
   PubMed Web of Science ®Google Scholar
• TakeuchiMKobataAStructures and functional roles of the sugar chains of human erythropoietinsGlycobiology199113373461820196
   PubMedGoogle Scholar
• EgrieJCBrowneJKDevelopment and characterization of darbepoetin alfaOncology (Williston Park)20021610 Suppl 11132212435169
   PubMed Web of Science ®Google Scholar
• HiguchiMOh-edaMKuboniwaHTomonohKShimonakaYOchiNRole of sugar chains in the expression of the biological activity of human erythropoietinJ Biol Chem1992267770377091560005
   PubMed Web of Science ®Google Scholar
• DigicayliogluMBichetSMartiHHLocalization of specific erythropoietin binding sites in defined areas of the mouse brainProc Natl Acad Sci U S A199592371737207731971
   PubMed Web of Science ®Google Scholar
• JuulSEYachnisATChristensenRDTissue distribution of erythropoietin and erythropoietin receptor in the developing human fetusEarly Hum Dev1998522352499808074
   PubMed Web of Science ®Google Scholar
• AnagnostouALiuZSteinerMErythropoietin receptor mRNA expression in human endothelial cellsProc Natl Acad Sci U S A199491397439788171022
   PubMed Web of Science ®Google Scholar
• RossertJEckardtKUErythropoietin receptors: their role beyond erythropoiesisNephrol Dial Transplant2005201025102815840686
   PubMed Web of Science ®Google Scholar
• LacombeCMayeuxPThe molecular biology of erythropoietinNephrol Dial Transplant199914Suppl 2222810334664
   PubMed Web of Science ®Google Scholar
• RatajczakJMajkaMKijowskiJBiological significance of MAPK, AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cellsBr J Haematol200111519520411722433
   PubMed Web of Science ®Google Scholar
• SilvaMBenitoASanzCErythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell linesJ Biol Chem1999274221652216910428780
   PubMed Web of Science ®Google Scholar
• KashiiYUchidaMKiritoKA member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transductionBlood20009694194910910908
   PubMed Web of Science ®Google Scholar
• YangCWLiCJungJYPreconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidneyFASEB J2003171754175512958199
   PubMed Web of Science ®Google Scholar
• EgrieJCBrowneJKDevelopment and characterization of novel erythropoiesis stimulating protein (NESP)Br J Cancer200184Suppl 131011308268
   PubMed Web of Science ®Google Scholar
• MacdougallICGraySJElstonOPharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patientsJ Am Soc Nephrol1999102392239510541299
   PubMed Web of Science ®Google Scholar
• PadhiDNiLCookeBMarinoRJangGAn extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysisClin Pharmacokinet20064550351016640455
   PubMed Web of Science ®Google Scholar
• LocatelliFOlivaresJWalkerREuropean/Australian NESP 980202 Study GroupNovel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiencyKidney Int20016074174711473657
   PubMed Web of Science ®Google Scholar
• NissensonARSwanSKLindbergJSRandomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patientsAm J Kidney Dis20024011011812087568
   PubMed Web of Science ®Google Scholar
• VanrenterghemYBárányPMannJFEuropean/Australian NESP 970200 Study GroupRandomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patientsKidney Int2002622167217512427142
   PubMed Web of Science ®Google Scholar
• WaradyBAArarMYLernerGNakanishiAMStehman-BreenCDarbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney diseasePediatr Nephrol2006211144115216724235
   PubMed Web of Science ®Google Scholar
• McKoyJMStonecashRECournoyerDEpoetin-associated pure red cell aplasia: past, present, and future considerationsTransfusion2008481754176218482185
   PubMed Web of Science ®Google Scholar
• MacdougallICCERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemiaCurr Hematol Rep2005443644016232379
   PubMedGoogle Scholar
• MacDougallICRobsonROpatrnaSPharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney diseaseClin J Am Soc Nephrol200611211121517699350
   PubMed Web of Science ®Google Scholar
• LevinNWFishbaneSCañedoFVMAXIMA Study InvestigatorsIntravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA)Lancet20073701415142117950856
   PubMed Web of Science ®Google Scholar
• KlingerMAriasMVargemezisVEfficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trialAm J Kidney Dis200750989100018037099
   PubMed Web of Science ®Google Scholar
• SulowiczWLocatelliFRyckelynckJPPROTOS Study InvestigatorsOnce-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weeklyClin J Am Soc Nephrol2007263764617699476
   PubMed Web of Science ®Google Scholar
• CanaudBMingardiGBraunJSTRIATA Study InvestigatorsIntravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III studyNephrol Dial Transplant2008233654366118586762
   PubMed Web of Science ®Google Scholar
• MacdougallICWalkerRProvenzanoRARCTOS Study InvestigatorsC.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trialClin J Am Soc Nephrol2008333734718287255
   PubMed Web of Science ®Google Scholar
• SpinowitzBCoyneDWLokCERUBRA Study InvestigatorsC.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeksAm J Nephrol20082828028918004064
   PubMed Web of Science ®Google Scholar
• Bouman-ThioEFransonKMillerBA phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjectsJ Clin Pharmacol2008481197120718812609
   PubMed Web of Science ®Google Scholar
• Pérez-RuixoJJKrzyzanskiWBouman-ThioEPharmacokinetics and pharmacodynamics of the erythropoietin mimetibody construct CNTO 528 in healthy subjectsClin Pharmacokinet20094860161319725594
   PubMed Web of Science ®Google Scholar
• SteadRBLambertJWesselsDEvaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteersBlood20061081830183416720830
   PubMed Web of Science ®Google Scholar
• WoodburnKWFanQWinslowSHematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia modelExp Hematol2007351201120817662888
   PubMed Web of Science ®Google Scholar
• MacdougallICRossertJCasadevallNA peptide-based erythropoietin-receptor agonist for pure red-cell aplasiaN Engl J Med20093611848185519890127
   PubMed Web of Science ®Google Scholar
• Affymax. Clinical Trials – Renal. Available from: http://www.affymax.com/view.cfm/50/Clinical-Trials---Renal. Accessed June 16, 2011.
   Google Scholar
• BernhardtWMWiesenerMSScigallaPInhibition of prolyl hydroxylases increases erythropoietin production in ESRDJ Am Soc Nephrol2010212151215621115615
   PubMed Web of Science ®Google Scholar
• BinleyKAskhamZIqballSLong-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapyBlood20021002406241312239150
   PubMed Web of Science ®Google Scholar
• BesarabABoltonWKBrowneJKThe effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetinN Engl J Med19983395845909718377
   PubMed Web of Science ®Google Scholar
• ParfreyPSFoleyRNWittreichBHSullivanDJZagariMJFreiDDouble-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart diseaseJ Am Soc Nephrol2005162180218915901766
   PubMed Web of Science ®Google Scholar
• DrüekeTBLocatelliFClyneNCREATE InvestigatorsNormalization of hemoglobin level in patients with chronic kidney disease and anemiaN Engl J Med20063552071208417108342
   PubMed Web of Science ®Google Scholar
• SinghAKSzczechLTangKLCHOIR InvestigatorsCorrection of anemia with epoetin alfa in chronic kidney diseaseN Engl J Med20063552085209817108343
   PubMed Web of Science ®Google Scholar
• PfefferMABurdmannEAChenCYTREAT InvestigatorsA trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseN Engl J Med20093612019203219880844
   PubMed Web of Science ®Google Scholar
• VaziriNDMechanism of erythropoietin-induced hypertensionAm J Kidney Dis19993382182810213636
   PubMed Web of Science ®Google Scholar
• Procrit. Clinical Study Report PR00-06-014 (CHOIR). Available from: http://download.veritasmedicine.com/PDF/CR004588_CSR.pdf. Accessed June 16, 2011.
   Google Scholar
• LocatelliFPisoniRLCombeCAnaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS)Nephrol Dial Transplant20041912113214671047
   PubMed Web of Science ®Google Scholar
• MessanaJMChuangCCTurenneMAssociation of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted modelAm J Kidney Dis20095350351219185402
   PubMed Web of Science ®Google Scholar
• SzczechLABarnhartHXInrigJKSecondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomesKidney Int20087479179818596733
   PubMed Web of Science ®Google Scholar
• SolomonSDUnoHLewisEFTrial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) InvestigatorsErythropoietic response and outcomes in kidney disease and type 2 diabetesN Engl J Med20103631146115520843249
   PubMed Web of Science ®Google Scholar
• FoleyRNCurtisBMParfreyPSHemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapyClin J Am Soc Nephrol200831669167518922988
   PubMed Web of Science ®Google Scholar